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Search Strategy and Selection Criteria section 
Data for this review were identified by searches of PubMed. References from relevant 
articles using the search terms „epilepsy, brain tumor, review“, which revealed 881 
citations, „epilepsy brain tumor chemotherapy“ (753 citations), „epilepsy, drug 
interactions, tumor“ (114 citations), „partial epilepsy randomized controlled trial“ (614 
citations) and „prognostic factors epilepsy glioma“ (30 citations) were considered. 
Articles were also identified through searches of the authors` own files. Only papers in 
English were reviewed. Data from controlled trials were regarded superior to data from 
uncontrolled series and the newest article was chosen, if multiple references to a similar 
topic were available. One abstract was included for novelty reasons. The final reference 
list was generated on the basis of originality and relevance to the broad scope of this 
review. 
 
 
 
SUMMARY 
  
The lifetime risk of suffering epileptic seizures is profoundly increased in cancer patients: 
approximately 20% of all patients with systemic cancer may develop brain metastases. 
These patients as well as patients with primary brain tumors carry a lifetime risk of 
epilepsy in the range of 20-80%. Moreover, exposure to chemo- or radiotherapy to the 
brain as well as cancer-related metabolic disturbances, stroke and infection may 
provoke seizures. The management of epilepsy in cancer patients includes (i) diagnosis 
and treatment of the underlying cerebral pathology, (ii) secondary prophylaxis using 
antiepileptic drugs, and (iii) limiting the impact of epilepsy and its treatment on the 
efficacy and tolerability of anti-cancer treatments, cognitive function and quality of life. 
Because of the specific concern of drug drug interactions, the pharmacological approach 
to epilepsy requires a multidisciplinary approach, specifically in a setting of rapidly 
increasing choices of agents both to treat cancer and cancer-associated epilepsy. 
 Introduction 
 
Epileptic seizures are a potentially life-threatening symptom of structural or metabolic 
brain dysfunction. They are among the most common presenting features of patients 
with primary brain tumors. They are also a frequent complication in patients with 
disseminated cancer, mostly because of solid brain metastasis or leptomeningeal 
disease, but may also be caused by exposure to chemotherapy or radiotherapy to the 
brain, stroke, infection, or general disturbances e.g. of salt or liver metabolism 
associated with systemic cancer progression. This review focuses on the relevance of 
epilepsy for clinical oncology with specific consideration of the practical management of 
epilepsy in cancer patients as well as the increasingly complex interactions between the 
pharmacological approaches to cancer versus cancer-associated epilepsy. For specific 
aspects related to epilepsy and cancer, the reader is referred to contemporary review 
articles on epilepsy in primary brain tumor patients,1,2 drug drug interactions3,4 and drug-
resistant epilepsy.5 
 
Seizures and epilepsy: their nature and classification 
An epileptic seizure is most often a transient event caused by abnormal excessive or 
synchronous neuronal activity in the brain and can often, but not always, be recognized 
clinically by symptoms and signs of neurological dysfunction, most commonly altered 
consciousness and uncontrolled motor activity. As such, seizures can occur in the 
presence of a transitory precipitating factor, e.g., metabolic disturbance or exposure to a 
proconvulsive agent, including anti-cancer pharmaceutics, and are then a symptom of 
an underlying condition. Epilepsy, in contrast, is a disorder of the brain characterized by 
 an enduring predisposition to generate epileptic seizures in the absence or presence of 
an underlying structural brain alteration. Accordingly, there are classifications of epileptic 
seizures as well as classifications of epileptic disorders.6 The distinction of seizures and 
epilepsy remains difficult in the context of brain tumors. In general, seizures can, as a 
symptom, herald the development of any structural brain disease and are then also best 
conceived as being symptomatic, e.g., of a brain tumor. Some patients suffer a single 
seizure that leads to the diagnosis of a benign tumor that can be resected, and the 
patient will never suffer a seizure again. In other patients, tumors remain stable with or 
without specific oncological treatment, but seizure control becomes a life-long 
therapeutic challenge. 
It is estimated that approximately 50 million people worldwide suffer from some form of 
epilepsy, with a lifetime risk of one in 10 individuals to experience at least one seizure. 
In infants, seizures more often reflect an epileptic disorder without identifiable 
morphological brain pathology whereas in adults and in particular in the elderly seizures 
are commonly the first symptom of an underlying structural brain alteration. Cancer 
patients typically suffer either tonic-clonic generalized seizures that may be secondary to 
a focal seizure when they have structural brain lesions, which is more common, or not 
when they are triggered, e.g., by metabolic disturbances or exposure to proconvulsive 
agents, including anti-cancer pharmaceutics. 
 
Interfaces of epilepsy and cancer 
 Cancer patients have a major risk of developing epileptic seizures in the course of their 
disease whereas patients with epilepsy do probably not exhibit an increased risk of 
cancer. Yet, it remains controversial whether anti-epileptic drug (AED) treatment may 
have an impact on the risk of developing cancer. Older AED like phenobarbital or 
phenytoin have been identified as tumor-promoting agents in animal studies whereas 
theoretical considerations led to the hypothesis that valproic acid may have tumor-
protective properties (see below).7,8 Eventually, neither hypothesis has been confirmed 
to be of relevance in human cancer patients. Some rare hereditary diseases, mostly 
tuberous sclerosis, but also the neurofibromatoses and von Hippel Lindau disease, 
share epileptic seizures and tumors as disease characteristics. Here, type and location 
of tumors are likely to modulate the seizure risk. The life-time risk of brain tumor patients 
to experience epileptic seizures is in the range of 20-80%.1 It is higher in patients with 
primary brain tumors than in patients with brain metastasis. Seizures may occur in 
cancer patients in the absence of CNS involvement. In fact, even in the context of 
epilepsy in a cancer patient with a brain lesion, it must not be assumed that all epileptic 
seizures are caused by that lesion although this is a priori very likely. Alternative causes 
provoking or facilitating seizures including medications, metabolic disturbances, stroke 
or infection, need to be specifically considered, excluded or addressed, too.9 
 
Management of epilepsy in tumor patients: general principles 
The goals of epilepsy management include understanding its origin, treating its cause 
where possible, preventing further seizures, and limiting their sequelae. The initial work-
up of a suspected seizure requires an assessment of the circumstances of that episode 
and a thorough consideration of alternative diagnoses, mostly syncope, migraine and 
 cerebral ischemia. History taking is commonly complemented by 
electroencephalography (EEG) and cardiological assessments, depending on the 
circumstances. At presentation of a first epileptic seizure, cerebral magnetic resonance 
imaging (MRI) is indicated and the preferred imaging method. This may lead to the 
diagnosis of a hitherto unknown primary brain tumor, metastatic presentation of a 
previously unknown systemic tumor (most frequently non-small cell lung cancer, but also 
breast cancer, melanoma or renal cell carcinoma), or spread to the central nervous 
system (CNS) in a known cancer patient. In general, effective tumor treatment 
consisting of surgical resection, radiotherapy, pharmacotherapy, or combinations 
thereof, is likely to contribute to seizure control in brain tumor patients.10 Brain tumor-
associated epilepsy has commonly been considered more difficult to treat than other 
types of epilepsy, however, this perception is not supported by robust data. If the brain 
tumor is the accepted cause of epilepsy in brain tumor patients, then it will be difficult to 
control epilepsy if tumor cannot be controlled. Conversely, it has not been demonstrated 
that patients with stable brain tumors and epilepsy achieve seizure less often than other 
epilepsy patients, e.g., by pharmacotherapy. 
Drug treatment-resistant epilepsy is commonly defined as a failure of adequate trials of 
two (or more) tolerated and appropriately dosed AED regimens to adequately control 
seizures.5,11 Resistance may be related to altered expression or activity of drug 
transporters at the blood brain barrier, limiting penetration to the tissue of seizure origin, 
altered expression or activity of the target molecules of AED, or underlying mechanisms 
of seizure generation that are not covered by the mode of action of currently available 
AED. Which of these reasons account for resistance to AED in brain tumor-associated 
epilepsy to what extent, remains controversial. Nevertheless, with the availability of new 
 classes of AED which are better tolerated, resulting in better treatment compliance, 
seizures can be controlled with drug therapy either as single agents or in combination in 
the great majority of patients. 
In addition to the specific treatment of the underlying brain tumor, pharmacotherapy is 
the mainstay of treating epilepsy in cancer patients (Table 1). The classification of drugs 
as first, second or third generation AED is inconsistently used in the literature. From a 
practical oncology perspective, the distinction of enzyme-inducing (EI) AED and non-EI-
AED is more relevant (see below). Many considerations support a thoughtful use of AED 
in patients with primary or metastatic brain tumors, including the possible resistance of 
the seizure disorder to AED, drug drug interactions, and unwanted effects from AED: 
rashes, drowsiness and cognitive alterations may severely affect quality of life.12 
Unwanted effects from AED may also be more common in (brain) cancer patients than 
in patients with other etiologies of epilepsy.13 This has most likely multiple reasons, 
notably comedications such as steroids and chemotherapy, but also exposure to 
radiotherapy as well as effects of the tumor itself, and psychiatric comorbidity, notably 
depression. Of note, cognitive side effects from AED have to be weighed against 
cognitive deterioration induced by seizures, which can be severe and prolonged, too. If 
AED are indicated following the guidelines below, it is recommended to use non-EI-AED 
rather than EI-AED and to dose a single agent adequately high, that is to the edge of the 
recommended dose without unwanted effects, before moving to double or triple AED 
combinations, which are more difficult to monitor in terms of drug drug interactions, 
tolerability, safety, and efficacy. There is no evidence that specific AED are more active 
than others in brain tumor-associated epilepsy. Formal comparative trials of AED 
specifically in brain tumors have rarely been conducted, and the primary choice of agent 
 varies among experts. The SANAD trials that had indicated preferential activity of 
lamotrigine in focal epilepsy and of valproic acid in generalized epilepsy14,15 cannot be 
simply extrapolated to patients with brain tumors. In the absence of randomized studies 
in the brain tumor population of patients with epilepsy, preferred drugs based on 
tolerability, interactions, and efficacy at present include valproic acid, levetiracetam,16,17 
lamotrigine,18 and possibly lacosamide.19 Expression of synaptic vesicle protein 2A 
(SV2A), the presumed target of levetiracetam, may predict response to the drug.20 Drug 
combinations that may be useful in cancer patients with epilepsy include valproic acid 
plus lamotrigine or levetiracetam or levetiracetam plus topiramate.18 The local delivery of 
AED via convection-enhanced delivery is feasible, but plays no role in clinical practice.21 
 
Are cancer patients at increased risk of epilepsy in the absence of CNS 
involvement? 
The most common cause of seizures in cancer patients is probably the development of 
solid brain metastases,9 but leptomeningeal involvement needs also consideration. 
Accordingly, the initial work-up of a first seizure in any cancer patient must include 
neuroimaging, preferably MRI to rule out brain metastases. Neuroimaging, however, 
may also reveal stroke or infectious complications, which may be more common in 
systemic cancer patients than in the general population. The work-up may also include a 
lumbar puncture to analyze the cerebrospinal fluid for malignant cells, microorganisms, 
lactate and protein. Moreover, various cancer chemotherapy regimens may provoke 
seizures in a minority of cancer patients, e.g., high-dose chemotherapy with ifosfamide 
or methotrexate.9 Chemotherapy-related seizures occurring in the absence of brain 
metastases usually do not necessitate long-term AED treatment. Rare syndromes of 
 paraneoplastic disorders with epilepsy have been linked to autoantibodies against ion 
channels and neurotransmitter receptors, and some of these are tumor-associated, e.g., 
antibodies to the N-methyl-D-aspartate (NMDA) type of glutamate receptors in patients 
with teratoma.22 
 
Epilepsy in systemic cancer patients with CNS involvement 
Solid brain metastases seem to cause seizures less frequently than primary brain 
tumors, which may be explained by their less infiltrative growth and their inability to 
biochemically modulate neuronal excitability. New-onset seizures in patients with known 
brain metastases may indicate hemorrhage into a metastatic lesion, notably in 
metastatic melanoma patients, or tumor progression with associated edema. Patients 
undergoing resection of single or multiple brain metastases do not require primary 
seizure prophylaxis before and after surgery if they have never suffered a seizure. 
 
Epilepsy in primary brain tumor patients 
The life-time incidence of epileptic seizures in patients with primary brain tumors varies 
by diagnosis, age and literature source and is estimated in the range of 20-80%. The 
incidence is relatively lower in some of the most malignant brain tumors such as 
glioblastoma and primary central nervous system (CNS) lymphoma, but higher in some 
more benign, but still infiltrative lesions such as World Health Organization (WHO) grade 
II diffuse gliomas. The reasons for these differences are multifold, but remain somewhat 
speculative. Typical features attributed a high seizure risk include location in the 
temporal lobe and cortical as opposed to white matter involvement. In this regard, 
oligodendroglial tumors are often located at the interface between cortex and white 
 matter and cause seizures frequently whereas primary CNS lymphomas are more 
commonly growing in the white matter and are usually not diagnosed because of an 
epileptic seizure. In some types of brain tumors such as dysembryoplastic 
neuroepithelial tumors, the natural course of the tumor is very benign, but the severity of 
epilepsy dictates the necessity for surgical intervention.23 In such instances, surgery 
should be performed at centers specialized in epilepsy surgery. In low-grade gliomas, 
complete resection, shorter seizure history < 1 year, seizures other than focal seizures, 
and previous seizure response to pharmacotherapy were associated with better seizure 
control after surgery.24 In general, surgical tumor resection may greatly contribute to the 
reduction of seizure frequency and severity in patients with brain tumor-associated 
epilepsy. Beyond surgical resection,25,26 other anti-tumor treatments such as 
radiotherapy and chemotherapy may improve seizure control e.g. in patients with low-
grade gliomas.27 Some patients treated with temozolomide chemotherapy report 
improvement of seizure frequency well before any objective tumor regression is 
demonstrated by neuroimaging. Another compelling example of a nonsurgical anti-tumor 
treatment that helped to improve epilepsy in more than half of patients was recently 
provided by the introduction of the mTOR inhibitor, everolimus, as an experimental 
agent to inhibit the growth of subependymal giant cell astrocytomas in patients with 
tuberous sclerosis.28 The rationale for everolimus is enhanced mTOR activity resulting 
from lack of upstream control exerted by the tuberin/harmartin complex.  
The proximate causes of why brain tumor patients suffer seizures at all and whether 
seizures in these patients have a different cause compared with other structural 
neurological brain disease such as multiple sclerosis or stroke have remained obscure. 
Little research has been done to specifically address this issue, as reviewed in depth 
 recently.2 Tumor location in proximity to cortical structures likely plays a role because 
neurons are considered the source of seizures. Ischemia of surrounding brain induced 
by tumor-associated changes in perfusion and the blood vessel network may contribute 
to seizure activity. Certain histological subtypes of primary brain tumors take up or 
release neurotransmitters and may thereby modulate neuronal excitability. Notably 
excessive glutamate levels have been proposed to mediate neuronal receptor-
dependent excitation triggering seizure activity. Accordingly, it has been proposed that 
glioblastoma patients suffering seizures have lower glutamine synthase levels than 
seizure-free patients.29 Glutamine synthase consumes ammonia and glutamate to 
generate glutamine. Moreover, tumor cells may also express ion channels and 
neurotransmitter receptors and the controversial discussion on the cellular origin of 
primary brain tumors with the possible link to neural progenitor cells have supported the 
hypothesis that some tumor cells themselves may generate electrical activity promoting 
seizures.30-32 Conversely, not only the tumor, but also the type of host response 
including inflammatory changes may determine the likelihood of developing symptomatic 
epilepsy.33 More recently, indoleamine 2,3-dioxygenase is a cytokine-inducible enzyme 
that participates in tryptophan and serotonin metabolism has been associated with 
seizure activity in inflammation.34 Due to its intimate role in different tumors including 
brain tumors,35 indoleamine 2,3-dioxygenase-mediated tryptophan catabolism may also 
be involved in seizures in brain tumor patients. Whether it is protective or promoting 
seizure activity remains to be shown, but would allow for an innovative treatment 
approach. 
 
Do AED exhibit intrinsic anti-tumor properties? 
 Intrinsic antitumor activity of certain AED and synergy with chemotherapy or 
radiotherapy have been suggested in some, but not all studies. For instance, phenytoin 
has been attributed anti-mitotic and anti-invasive properties, and valproic acid has been 
suggested to induce cell differentiation, growth arrest, apoptosis, autophagy, and these 
effects were proposed to be mediated by histone deacetylase (HDAC) inhibitory 
properties.36-40 These issues were most often addressed in the context of gliomas, given 
the high need for AED treatment in this patient population. We did not observe cytotoxic 
or antiproliferative effects of either carbamazepine, phenytoin or valproic acid in cultured 
glioma cells at concentrations likely to be achieved in vivo.41 Yet, valproic acid alone 
delayed growth in medulloblastoma xenograft models in severe combined 
immunodeficiency mice in the apparent absence of relevant systemic toxicity,37 but 
because of differences in valproic acid metabolism of valproic acid in mouse and man, 
these interesting observations in mice are difficult to extrapolate to human patients. 
Moreover, valproic acid when combined with the DNA (cytosine-5) methyltransferase 
inhibitor 5-aza-2’-deoxycytidine reduced the incidence of medulloblastomas and 
rhabdomyosarcomas in heterozygous Patched 1 knockout mice.38 The same 
combination induced expression of the candidate tumor antigen NY-ESO-1 in cultured 
glioma cells.39 If AED act via HDAC inhibition only to potentially inhibit tumor growth 
when administered alone, their antitumor activity can be predicted to be low, given that 
much more powerful HDAC inhibitors have shown rather limited single agent activity in 
human cancer patients.42 
 
Interactions of cancer therapy and AED: tolerability 
 Pharmacokinetic as opposed to pharmacodynamic interactions of AED and various anti-
cancer drugs are the most important area to consider for the general oncologist at the 
interface between cancer care and epilepsy.3,4 Although many AED are metabolized in 
the liver, only certain agents like phenytoin, carbamazepine and derivatives, and 
phenobarbital, induce CYP450-dependent hepatic enzymes and thus increase their own 
metabolism and more importantly, the metabolism and degradation of many commonly 
used cytotoxic agents (Table 2). Most new AED are neutral in this regard whereas 
valproic acid may inhibit metabolism and consequently augment half-life and toxicity of 
concomitant medications. For the design of clinical trials, also outside neurooncology, 
this calls for groups separated for the use of EI-AED or non-EI-AED, since maximal 
tolerated doses as well as effective doses may be relevantly different. Alternatively, 
many new trials per se exclude patients on EI-AED. The spectrum of AED as well as the 
spectrum of anti-cancer agents is steadily increasing. There are various websites 
beyond Pubmed or Medline where information on such interactions can be retrieved. 
These require regular up-dating. Importantly, the risk of using such EI-AED does not 
only include the risk of delivering expensive, but necessarily ineffective medical cancer 
therapy, but also a sudden increase in toxicity and loss of tolerability when such EI-AED 
are withdrawn and replaced by non-EI-AED. Thus, special attention to drug drug 
interactions is required not only when implementing, but also when tapering AED. 
Conversely, the enzyme-inhibiting effect of valproic acid appears clinically of lesser 
importance, although increased myelosuppression may develop in patients receiving 
nitrosoureas or cisplatinum-based chemotherapy or temozolomide concomitantly with 
valproic acid.43,44 There are also safety concerns regarding the choice of AED in cancer 
patients beyond drug-drug interactions. Various neurosurgeons fear an increased risk of 
 peri-operative bleeding complications in valproic acid-treated brain tumor patients, 
although this is not supported by the literature.45,46 The risk of severe skin toxicity is 
increased when patients are treated with phenytoin or carbamazepine or oxcarbazepine 
not only in combination with procarbazine, but also with radiotherapy.47 Finally, EI-AED 
decrease the bioavailability of steroids, necessitating careful clinical monitoring when EI-
AED are newly introduced in steroid-dependent brain tumor patients. Conversely, when 
EI-AED are replaced by non-EI-AED, it should be assessed whether steroid doses can 
be lowered. Based on these considerations and the unfavorable safety profile of these 
drugs regarding cognitive function, we propose to select a priori newer AED, which are 
devoid of such interactions. 
 
Interactions of cancer therapy and AED: efficacy and survival 
Because of the enzyme-inducing activity described above, older AED such as 
phenytoin, phenobarbital or carbamazepine may enhance the metabolism of many 
commonly administered chemotherapy agents and thus decrease their efficacy (Table 
2). Accordingly, there is now a trend to favor non-EI-AED for cancer patients, in order to 
allow effectively the administration of chemotherapy and targeted agents that often show 
increased hepatic metabolism in EI-AED-treated patients. Conversely, it has not been 
demonstrated that the enzyme inhibitory activity of valproic acid results in clinically 
relevant increases in anti-cancer drug levels and that this increases their activity through 
a pharmacokinetic mechanism. 
Intrinsic anti-tumor activities (see above) or pharmacodynamic potentiation of 
radiotherapy or chemotherapy have been proposed to be mediated by some AED. 
However, there is only limited data from in vitro studies indicating additive or synergistic 
 activity of AED with cancer therapeutics. For instance, we did not observe a modulation 
of the cytotoxic or antiproliferative effects of several anti-cancer drugs, including 
vincristine, cytarabine, doxorubicin, cisplatin, 3-bis-(2-chloroethyl)-1-nitrosourea (BCNU) 
and teniposide (VM26), by either carbamazepine, phenytoin or valproic acid in cultured 
glioma cells at concentrations likely to be achieved in vivo.41 More recently, 
levetiracetam has been proposed to sensitize glioblastoma cells to temozolomide via 
suppression of O6-methylguanine-DNA-methyltransferase expression,48 thus targeting 
one of the major resistance pathways of alkylating agent chemotherapy.49 
Since the life-time risks of glioblastoma patients to experience epileptic seizures as well 
as AED-associated toxicity are considerable, and since these patients are now 
commonly exposed to chemotherapy, there has traditionally been significant interest in 
the choice of AED in glioblastoma. A retrospective analysis of three trials performed by 
the North Central Cancer Treatment Group indicated a possible association of EI-AED 
use, but not of seizure history, with a favorable outcome in glioblastoma patients.50 Yet, 
the implications of this observation remain unclear in that the chemotherapy regimens 
used in these trials are not considered active.51 Accordingly, we retrospectively 
assessed a potential predictive association with outcome of AED use within the pivotal 
trial of radiotherapy alone versus radiotherapy plus concomitant and adjuvant 
temozolomide for newly diagnosed glioblastoma that was conducted by the European 
Organization for Research and Treatment of Cancer and the National Cancer Institute of 
Canada Clinical Trials Group.52 We identified 387 patients (68% of all patients) who 
received any AED; 110 patients (28% of those receiving AED) were prescribed 
exclusively non-EI-AED, mostly valproic acid, while the others received at least one EI-
AED, either phenytoin, carbamazepine, oxcarbazepine, or phenobarbital. We specifically 
 compared three groups of patients, those without AED, those treated with valproic acid 
alone, and those treated with EI-AED only. After controlling for potentially confounding 
factors, we still observed a significant increase in overall survival of patients treated with 
valproic acid in the experimental arm, but not in the radiotherapy arm, suggesting a 
specific interaction between valproic acid and temozolomide chemotherapy. This 
association remains after adjusting for potentially confounding factors and inbalances. 
Moreover, hematological toxicity in patients treated with chemoradiotherapy and valproic 
acid was increased.44 Nevertheless, our analysis has some limitations and should be 
interpreted with caution. The data were generated from an unplanned and insufficiently 
powered retrospective analysis with limited statistical power. AED use for the purpose of 
this analysis refers only to baseline use, that is, at study entry when patients were 
treated with radiotherapy with or without temozolomide chemotherapy, but no detailed 
data on further AED treatment were collected during the course of the study. The reason 
for the prescription of AED was not recorded, thus, patients may have been receiving 
AED because of a seizure at disease presentation or as primary prophylaxis during the 
peri- and postoperative phase. We assume that only a minority of patients was 
maintained on valproic acid throughout the planned six cycles of adjuvant 
temozolomide, raising the possibility that any sensitization to chemoradiotherapy by 
valproic acid might have been underestimated here. At least two mechanisms for this 
improved efficacy of temozolomide chemotherapy conferred by comedication with 
valproic acid may be considered. Temozolomide is a prodrug converted to 3-methyl-
(triazen-1-yl)imidazole-4-carboxamide which is either hydrolyzed or unchanged prior to 
excretion. No effect of phenytoin, carbamazepine, or phenobarbital on temozolomide 
clearance has been observed whereas valproic acid decreased its clearance by 5% 
 (http://www.temodar.com ). To some extent, the increased hematological toxicity during 
adjuvant temozolomide chemotherapy with valproic acid may thus be related to an 
increased bioavailability of temozolomide. Yet, thrombocytopenia is not an uncommon 
side effect in patients treated with valproic acid alone. Moreover, the negative result for 
temozolomide dose intensification in the Radiation Therapy Oncology Group 0525 trial53 
strongly argues against the hypothesis that valproic acid simply increases the 
biologically active dose of temozolomide. Increased hematological toxicity has 
previously been observed when glioma patients were co-treated with valproic acid and 
nitrosourea-based chemotherapy, but survival data by AED use were not reported.43 
Alternatively, our observation may lend support to the notion that HDAC inhibitory 
properties of valproic acid sensitize glioma cells for temozolomide. The EC50 for valproic 
acid-induced HDAC inhibition is 500 M,36 which probably exceeds the clinically 
achieved plasma concentrations. Yet, some glioblastoma patients reoperated after 
exposure to valproic acid exhibit evidence of HDAC inhibition.54 A prolonged survival of 
14 months versus 11 months was observed in glioblastoma patients treated with 
adjuvant CCNU who received a non-EI-AED, mainly valproic acid, compared with 
patients on EI-AED, mainly carbamazepine.55 A phase I dose escalation trial of valproic 
acid combined with 5-fluorouracil, epirubicin, and cyclophosphamide confirmed that 
HDAC inhibition could be achieved in vivo.56 Yet, a phase I trial exploring valproic acid 
plus dacarbazine/interferon- chemoimmunotherapy in metastatic melanoma showed 
only moderate tolerability, but no indication of enhanced activity.57 Exploratory trials 
using HDAC inhibitors more potent than valproic acid such as vorinostat in combination 
with temozolomide radiochemotherapy may provide further support for this hypothesis. 
 Selective HDAC inhibitors might also have a preferred tolerability profile compared with 
valproic acid, which induces weight gain, alopecia and tremor in some patients (Table 
1). In any case, this analysis from a randomized phase III trial supports the view that the 
choice of AED in brain tumor patients may affect survival.44 
 
Frequently asked questions (FAQ) regarding epilepsy and cancer 
The interface between cancer and epilepsy currently provides an area of many 
interesting observations, active clinical and laboratory research, and opportunities to 
improve quality of life and outcome in cancer patients. Yet, there are at the same time 
many questions that arise in daily clinical practice and for many of which there are no 
answers that could be based on several or even one adequate clinical trial. 
Table 3 summarizes some of these classical questions (and answers). Improved cancer 
therapy, as well as early and regular prenatal care, allow normal pregnancies and 
pregnant women with cancer to deliver healthy babies. Here it may be important to 
attempt decreasing pharmacotherapy to monotherapy and to taper doses of AED to the 
lowest possible level. There is no anticonvulsant of choice; however, the best safety 
data are available for lamotrigine.58 In women who have not had a seizure for 2-5 years, 
an attempt at complete AED withdrawal is warranted. Patients should be offered 
preconceptual genetic counseling.  
Almost a quarter of people diagnosed with epilepsy are >60 years of age. Underlying 
factors are discovered in a greater proportion than in younger patients, including 
cerebrovascular disease, dementia, trauma and tumors. Treatment should be kept at the 
lowest effective dose since there is an increased risk of side effects and idiosyncratic 
reactions.59 There is an increased risk of pharmacological interactions due to 
 polypharmacy. The likelihood and severity of adverse reactions is increased. Since long-
term AED treatment is considered an independent risk factor for osteoporosis, calcium 
and vitamine D supplements should be considered with AED treatment in the elderly. 
Further, epilepsy is associated with an increased risk of mental health disorders, such 
as anxiety, depression and suicidal thoughts.60 
 
Conclusions 
Recognition and secondary prophylaxis of seizures and epilepsy in cancer patients are a 
major challenge that commonly requires a multidisciplinary approach. The major goals, 
freedom from seizures, achieving seizure control with an acceptable safety and 
tolerability of AED, and achieving seizure control without interfering with the efficacy of 
cancer treatment, can often be achieved, however, careful monitoring and thoughtful 
clinical decision making are required. 
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 Table 1. AED profiles. 
 
      
 Mode of 
action 
Daily dose 
(mg) 
Therapeutic 
serum level 
(µg/ml) 
Unwanted effects  Drug int
      
Phenobarbital GABAergic, 
prolonging 
chloride 
channel 
opening 
50-300 10-40 Sedation, cognition, 
allergy 
Enzyme 
P450) 
      
Primidone GABAergic, 
prolonging 
chloride 
channel 
opening 
500-1500 5-15 Sedation, cognition Enzyme 
P450) 
      
Clobazam GABAergic, 
facilitating 
chloride 
channel 
opening 
10-30 0.1-0.4 Sedation Sedative
medicati
      
Clonazepam GABAergic, 
facilitating 
chloride 
channel 
opening 
0.5-4 0.02-0.08 Sedation, cognition Sedative
medicati
      
Phenytoin Sodium 
channel 
blocker (fast 
inactivation) 
200-350 10-20 Dizziness, allergy, 
hepatotoxicity, gingival 
hyperplasia, cerebellar 
atrophy, skin toxicity 
Enzyme 
P450), in
requirem
      
Carbamazepine Sodium 
channel 
blocker (fast 
inactivation) 
600-2000 4-8 Dizziness, nausea, 
ataxia, hyponatremia, 
leukopenia, 
hepatotoxicity, skin 
toxicity 
Enzyme 
P450), in
requirem
 
       
Oxcarbazepine Sodium 
channel 
blocker (fast 
inactivation) 
900-2400 10-35 Hyponatremia, 
leukopenia, skin toxicity 
Enzyme 
P450), le
      
Valproate Unclear, 
inhibition of ion 
channels (?), 
promotion of 
GABA 
signaling (?) 
1200-2400 50-100 Tremor, weight, 
coagulation disorders, 
thrombocytopenia, 
teratogenicity 
Multiple 
glucuron
hydrolas
 increa
chemoth
      
Lamotrigine Sodium 
channel 
blocker (fast 
inactivation) 
100-300 2-15 Skin toxicity, tremor, 
sedation (rare) 
Carbama
phenoba
reduce la
whereas
lamotrigi
      
Gabapentin Calcium 
channel 
blocker (high 
voltage), 
GABA agonist 
(?) 
900-3000 2-20 Sedation, weight gain Limits bi
and may
morphine
      
Pregabaline Calcium 
channel 
blocker (high 
voltage) 
150-600 2-5 Sedation, weight gain No relev
      
Topiramate Multiple: 
sodium 
channel 
blocker, GABA 
agonist, 
NMDA 
receptor 
antagonist 
50-200 2-20 Sedation, fatigue, 
inappetence, weight 
loss, psychosis 
May redu
contrace
      
Levetiracetam SV2A receptor 
binding 
1000-3000 3-30 Sedation (rare), 
psychiatric side effects 
No relev
      
Lacosamide Sodium 100-400 10-20 Dizziness, nausea, No relev
 channel 
blocker (slow 
inactivation), 
CRMP2 
binding 
headache, cognition, 
skin toxicity 
      
Zonisamide Multiple 300-500 20-30 Dizziness, ataxia, 
anorexia 
No or mi
cytochro
may redu
      
Tiagabine GABAergic, 
blocks 
synaptic 
GABA uptake
15-70 0.02-0.08 Dizziness, fatigue Levels a
cotreatm
      
Vigabatrin GABAergic, 
inhibits GABA 
transaminase 
200-300 0.8-36 Visual field defects, 
fatigue, sedation 
Reduces
25% 
 
CRMP2, collapsin response mediator protein-2; GABA, -aminobutyric acid; NMDA, N-
methyl-D-asparate; SV2A, synaptic vesicle 2A; 
 
 Table 2. Commonly used anti-cancer drugs negatively affected by EI-AED 
comedication. 
 
Alkylating agents Nitrosoureas: carmustine (BCNU), lomustine 
(CCNU), nimustine (ACNU), fotemustine; 
thiotepa; cyclophosphamide; ifosfamide 
Mitotic inhibitors Vinca-alcaloids: vincristine, vinorelbine; 
paclitaxel, docetaxel 
Topoisomerase inhibitors / 
DNA-damaging agents 
irinotecan, topotecan, etoposide, adriamycin 
 
Antimetabolites Methotrexate, pemetrexate  
Signal transduction inhibitors Imatinib, erlotinib, gefinitib, sorafenib, 
temsirolimus, everolimus, vemurafenib 
Proteasome inhibitors Bortezomib 
 
 
 Table 3. Frequently asked questions (FAQ) in the context of epilepsy and cancer. 
 
Should all brain tumor patients 
receive AED? 
There is no evidence that primary prophylaxis with AED decrease
ever seizure in brain tumor patients.13,61,62 This statement is base
examining phenobarbital, phenytoin, or valproic acid and may not
extrapolated to other AED. 
 
Should all brain tumor patients 
who undergo a craniotomy receive 
AED? 
 
No, there is also no evidence that primary prophylaxis with AED d
of a first-ever seizure in brain tumor patients undergoing cranioto
Should I take my patient off AED if 
these were instituted without good 
reason? 
 
Yes, but slowly not to provoke seizures, and specific attention to 
pharmacokinetics of co-medications is warranted when EI-AED a
Should all brain tumor patients 
receive AED after the first seizure?
 
Yes, because epilepsy is highly likely to be symptomatic and requ
further seizures until the tumor has been adequately treated. 
How long should brain tumor 
patients with a presenting seizure, 
who remain seizure-free after 
surgery, receive AED? 
 
In the absence of randomized trial data, tapering and discontinua
weeks is recommended, depending on histology and tumor contr
seizures in this patient population is strongly associated with tum
progression. 
 
How long should brain tumor 
patients, who experience seizures 
after surgery, be maintained on 
anticonvulsants? 
 
How long should brain tumor 
patients, who experience seizures 
and never had surgery, be 
maintained on anticonvulsants? 
 
 
 
The occurrence of seizures later than 48–72 h after surgery, or w
in brain tumor patients with no other predisposing factor usually in
for long-term AED treatment. Often patients will never become se
experience only a reduction in seizure frequency and severity. Th
and eventually discontinue AED requires the consideration of var
factors, notably tumor control. The risks of recurrent seizures, e.g
bony metastases or anticoagulation, need to be weighed against 
receiving AED. In a general population of patients with (largely) id
free from seizures for 2 years, the rate of relapse within the first tw
withdrawal is in the range of 50%,63 and is probably higher in bra
with symptomatic epilepsy. The social implications of seizure recu
driving, work, and leisure activities, need to be considered, too. 
 
Which AED is best for cancer 
patients with epilepsy? 
 
EI-AED should be avoided with few exceptions. Valproic acid and
be dosed quickly and intravenously.16,17 Lamotrigine needs to be 
mainly due to the allergic potential but has otherwise favourable t
and efficacy. 
 
What is the role of serum level 
monitoring in cancer patients on 
AED? 
Routine monitoring of serum levels of AED is not required and als
available for all agents described in Table 2. Rationales include (
patients’ compliance, (ii) to assess whether physical or mental sy
may represent AED toxicity and (iii) to assess whether appropriat
 achieved in AED-unresponsive patients who continue to experien
 
Which of my cancer patients 
require monitoring by EEG? 
 
Monitoring by EEG is not required for the majority of cancer patie
is of value in the initial work-up of suspected seizures and if there
about continuous seizure activity in the course of disease. The EE
important role in the management of patients with biologically ben
tumors where epilepsy is the major burden of the disease. 
 
Which of my cancer patients 
should be allowed to drive? 
Country-specific regulations need to be considered. Seizure cont
control are required. However, it is important to recognize that tum
neurological deficits other than seizures, such as hemianopia or m
may interfere with the competence to drive. We recommend not t
an interval following brain surgery or when there is overt brain tum
irrespective of a positive or negative seizure history. Further, driv
permitted during tapering and withdrawing AED. 
 
 
 
